Iomed says agrees to be acquired by ReAble Therapeutics

(Reuters) - The deal is valued at about $22 million and represents a premium of about 38 percent over Iomed's Thursday closing price of $1.99.



Following the acquisition, Iomed will be a wholly-owned subsidiary of ReAble, the statement added.


Read more at Reuters.com Mergers News